Pfizer tests drug interaction in tiny early study
NCT ID NCT07575945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study looks at whether the antifungal itraconazole changes how the body handles a new drug called PF-08642534. Fourteen healthy adults will take the study drug with and without itraconazole. The goal is to see how the drug levels change, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08642534 and itraconazole
What this could lead to
If successful, this study will show whether itraconazole changes how PF-08642534 is processed, helping guide future dosing recommendations.
What could go wrong
This is a very early Phase 1 study in only 14 healthy people, so results may not predict effects in patients or reflect real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Haven Clinical Research Unit
New Haven, Connecticut, 06511, United States